Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection

Biomaterials

Volumn 34, Issue 15, 2013, Pages 3846-3857

  Zhang, Jinjin ^a   Mulvenon, Andrea ^a   Makarov, Edward ^b   Wagoner, Jill ^c   Knibbe, Jaclyn ^b   Kim, Jong Oh ^a   Osna, Natalia ^c   Bronich, Tatiana K ^a   Poluektova, Larisa Y ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Amphiphatic helical peptide; Anionic poly (amino acid) based block copolymer; HCV; HIV 1; Human hepatoma cell line Huh7.5; Macrophages

Indexed keywords

HCV; HELICAL PEPTIDE; HIV-1; HUMAN HEPATOMA CELL LINES; POLYAMINO ACIDS;

AMINO ACIDS; BLOCK COPOLYMERS; CELL CULTURE; DISEASES; IONIC STRENGTH; MACROPHAGES; PATIENT TREATMENT; PH; VIRUSES;

PEPTIDES;

AMPHIPHATIC ALPHA HELICAL PEPTIDE; ANTIVIRAL PEPTIDE NANOCOMPLEX; ANTIVIRUS AGENT; COMPLEMENT COMPONENT C5A; COPOLYMER; NANOCARRIER; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; IONIC STRENGTH; LYMPHOCYTE; MIXED INFECTION; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN ASSEMBLY; VIRUS LOAD;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CIRCULAR DICHROISM; COINFECTION; ENDOCYTOSIS; HEMOLYSIS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MICE; MICROSCOPY, ATOMIC FORCE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PROTEOLYSIS; TRYPSIN; VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84874954823     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.026     Document Type: Article

References (43)

1. Deming P., McNicholl I.R. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2011, 31:357-368.
2. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-S9.
3. Staples C.T., Rimland D., Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
4. Denissen J.F., Grabowski B.A., Johnson M.K., Buko A.M., Kempf D.J., Thomas S.B., et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 1997, 25:489-501.
5. Puoti M., Manno D., Nasta P., Carosi G. The burden of HIV and hepatitis C virus coinfection. Curr Opin HIV AIDS 2007, 2:460-465.
6. Chen T.Y., Ding E.L., Seage Iii G.R., Kim A.Y. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49:1605-1615.
7. Buskin S.E., Barash E.A., Scott J.D., Aboulafia D.M., Wood R.W. Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals. World J Gastroenterol 2011, 17:1807-1816.
8. Rosenthal E., Poiree M., Pradier C., Perronne C., Salmon-Ceron D., Geffray L., et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003, 17:1803-1809.
9. Lai A.R., Tashima K.T., Taylor L.E. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. AIDS Patient Care STDS 2006, 20:678-692.
10. Daar E.S., Lynn H., Donfield S., Gomperts E., O'Brien S.J., Hilgartner M.W., et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001, 183:589-595.
11. Ragni M.V., Nalesnik M.A., Schillo R., Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009, 15:552-558.
12. Reiche E.M., Bonametti A.M., Morimoto H.K., Morimoto A.A., Wiechemann S.L., Matsuo T., et al. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population. Int J Mol Med 2008, 21:387-395.
13. Seden K., Back D., Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010, 65:1079-1085.
14. Shivraj S.O., Chattopadhya D., Grover G., Kumar A., Baveja U.K. Role of HCV coinfection towards disease progression and survival in HIV-1 infected children: a follow-up study of 10 years. J Trop Pediatr 2006, 52:206-211.
15. Serpaggi J., Chaix M.L., Batisse D., Dupont C., Vallet-Pichard A., Fontaine H., et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006, 20:233-240.
16. Vallet-Pichard A., Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006, 44:S28-S34.
17. Rallon N.I., Naggie S., Benito J.M., Medrano J., Restrepo C., Goldstein D., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29.
18. Alestig E., Arnholm B., Eilard A., Lagging M., Nilsson S., Norkrans G., et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011, 11:124.
19. Graham C.S., Wells A., Liu T., Sherman K.E., Peters M., Chung R.T., et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006, 20:345-351.
20. Bobardt M.D., Cheng G., de Witte L., Selvarajah S., Chatterji U., Sanders-Beer B.E., et al. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A 2008, 105:5525-5530.
21. Cheng G., Montero A., Gastaminza P., Whitten-Bauer C., Wieland S.F., Isogawa M., et al. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2008, 105:3088-3093.
22. Lin Q., Fang D., Hou X., Le Y., Fang J., Wen F., et al. HCV peptide (C5A), an amphipathic alpha-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes. J Immunol 2011, 186:2087-2094.
23. Batrakova E.V., Li S., Reynolds A.D., Mosley R.L., Bronich T.K., Kabanov A.V., et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem 2007, 18:1498-1506.
24. Gaydess A., Duysen E., Li Y., Gilman V., Kabanov A., Lockridge O., et al. Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem Biol Interact 2010, 187:295-298.
25. Harada A., Kataoka K. Pronounced activity of enzymes through the incorporation into the core of polyion complex micelles made from charged block copolymers. J Control Release 2001, 72:85-91.
26. Yuan X., Harada A., Yamasaki Y., Kataoka K. Stabilization of lysozyme-incorporated polyion complex micelles by the omega-end derivatization of poly(ethylene glycol)-poly(alpha, beta-aspartic acid) block copolymers with hydrophobic groups. Langmuir 2005, 21:2668-2674.
27. Lee Y., Fukushima S., Bae Y., Hiki S., Ishii T., Kataoka K. A protein nanocarrier from charge-conversion polymer in response to endosomal pH. J Am Chem Soc 2007, 129:5362-5363.
28. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
29. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001, 7:927-933.
30. Gendelman H.E., Orenstein J.M., Martin M.A., Ferrua C., Mitra R., Phipps T., et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988, 167:1428-1441.
31. Reardon J.E., Miller W. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. J Biol Chem 1990, 265:20302-20307.
32. Poluektova L.Y., Munn D.H., Persidsky Y., Gendelman H.E. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 2002, 168:3941-3949.
33. Gorantla S., Santos K., Meyer V., Dewhurst S., Bowers W.J., Federoff H.J., et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol 2005, 79:2124-2132.
34. Gorantla S., Sneller H., Walters L., Sharp J.G., Pirruccello S.J., West J.T., et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol 2007, 81:2700-2712.
35. Cota M., Kleinschmidt A., Ceccherini-Silberstein F., Aloisi F., Mengozzi M., Mantovani A., et al. Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. J Neurovirol 2000, 6:75-83.
36. Gorantla S., Makarov E., Finke-Dwyer J., Gebhart C.L., Domm W., Dewhurst S., et al. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 2010, 184:7082-7091.
37. Hamblin M.R., Miller J.L., Rizvi I., Loew H.G., Hasan T. Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer 2003, 89:937-943.
38. Fredericksen B.L., Wei B.L., Yao J., Luo T., Garcia J.V. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002, 76:11440-11446.
39. Miyauchi K., Kozlov M.M., Melikyan G.B. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog 2009, 5:e1000585.
40. Miyauchi K., Kim Y., Latinovic O., Morozov V., Melikyan G.B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
41. Sharma N.R., Mateu G., Dreux M., Grakoui A., Cosset F.L., Melikyan G.B. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem 2011, 286:30361-30376.
42. Meertens L., Bertaux C., Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 2006, 80:11571-11578.
43. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006, 80:6964-6972.